HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Dermatology1230 papers

Psoriasis of scalp

Last edited: 4/23/2026

Overview

Psoriasis of the scalp is a chronic inflammatory skin condition characterized by red, scaly patches, often accompanied by itching and discomfort. It commonly occurs in conjunction with psoriasis affecting other body areas but can present as an isolated scalp manifestation. 29

Diagnosis

Clinical presentation of erythematous, scaly plaques on the scalp.

May involve scalp examination under magnification for detailed assessment.

No specific laboratory tests; diagnosis is primarily clinical.

Consider ruling out other scalp conditions like seborrheic dermatitis or fungal infections through relevant tests if clinically indicated. 2 3 29

Management

First-line treatments: Topical therapies such as corticosteroids, vitamin D analogs (e.g., calcipotriene), and coal tar preparations.

Adjunctive treatments: Phototherapy (UVB or PUVA) for extensive scalp involvement.

Systemic therapies: For moderate to severe cases, consider methotrexate, cyclosporine, or newer biologic agents targeting TNF-α, IL-17, or IL-23 pathways (e.g., adalimumab, secukinumab, ixekizumab). 2 17 20 29

Special Populations

Pregnancy: Use topical treatments preferentially; systemic treatments require careful risk-benefit assessment, avoiding known teratogens like methotrexate. 16

Pediatrics: Tailored approach with emphasis on topical therapies; biologic agents should be considered cautiously based on disease severity and response to other treatments. 18

Comorbidities: Patients with cardiovascular risk factors may benefit from treatments that reduce systemic inflammation, such as IL-17 or IL-23 inhibitors, to mitigate cardiovascular risks. (Evidence: Moderate) 8 9 59

Key Recommendations

Initiate treatment with topical agents for mild scalp psoriasis, escalating to systemic therapies for moderate to severe cases. (Evidence: Strong) 2 20

Consider the cardiovascular risk profile when selecting systemic treatments, favoring biologics that have shown benefits in reducing cardiovascular events. (Evidence: Moderate) 8 9 59

In pregnant patients, prioritize topical therapies and consult guidelines for safe systemic options if necessary. (Evidence: Moderate) 16

For pediatric patients, start with conservative treatment approaches and tailor interventions based on disease severity and response. (Evidence: Expert opinion) 18

References

Showing 100 most recent of 1066 indexed papers.

1 Puig L, Carrascosa JM, Rivera R, Vilarrasa E, de la Cueva P, López-Ferrer A. Generalized Pustular Psoriasis: Review and Consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas dermo-sifiliograficas 2026. link 2 Gupta AK, Bamimore MA, Wang T, Piguet V, Talukder M. Relative Efficacy of Immunomodulatory Monotherapies for Psoriasis of the Scalp: A Network Meta-Analysis Study. Journal of cosmetic dermatology 2026. link 3 Dege T, Steffens O, Kiesel Ö, Bychkova I, Leichtfuss L, Schulze-Hagen T et al.. Joint Assessment Matters: Diagnostic and Therapeutic Benefits of Interdisciplinary Psoriasis Care. Advances in therapy 2026. link 4 Demet AN, Kaynak E, Ahmet M. ChatGPT and DeepSeek in Dermatologic Practice: Do Artificial Intelligence Models Adhere to Psoriasis Treatment Guidelines?. Journal of drugs in dermatology : JDD 2026. link 5 Costanzo A, Bardazzi F, Burlando M, Campanati A, Carrera C, Dapavo P et al.. Toward the definition of moderate psoriasis: an expert opinion. The Journal of dermatological treatment 2026. link 6 Thimjo J, Das D, Enerbäck C, Ludvigsson J. Childhood infections as predisposing factors to developing psoriasis vulgaris into early adulthood. The British journal of dermatology 2026. link 7 Lin X, Guo L, Lin T, Yan C, Huang X, Cheng Y et al.. Disproportionality analysis of adverse events associated with bimekizumab: a real-world study based on FDA Adverse Event Reporting System (FAERS) Database. Naunyn-Schmiedeberg's archives of pharmacology 2026. link 8 Djukanovic L, Skiljevic D, Nikolic M, Malinic M, Popadic S, Radmili O et al.. Atherogenic Lipoprotein Burden, Metabolic Stress and Immune Activation Associated with Coronary Atherosclerosis in Patients with Psoriasis. International journal of molecular sciences 2026. link 9 Geiger J, Gill B, Liew J, Putman M, Singla S. Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis and Its Association With Risk of Major Adverse Cardiac Events. The Journal of rheumatology 2026. link 10 Tartaglia J, Ponzano M, Mazzetto R, Sernicola A, Ciolfi C, Tona F et al.. Cardiovascular Imaging in Psoriasis: A Critical Review of Current Evidence, Techniques, and Therapeutic Implications. American journal of clinical dermatology 2026. link 11 Rivera-Díaz R, Joven B, Gotor-Rivera A, Hernández J. Mortality Outcomes in Patients With Plaque Psoriasis and Hidradenitis Suppurativa: The Role of Biologic Therapy. Actas dermo-sifiliograficas 2026. link 12 Watabe H, Ishibashi Y, Go K, Nakajima K, Tanabe Y, Akashi YJ et al.. Clinical Profiles of Psoriasis Patients With Coronary Artery Calcification and Assessment of Acute Coronary Syndrome Risk Factors Using Coronary Computed Tomography Angiography-Estimated Fractional Flow Reserve. The Journal of dermatology 2026. link 13 Zhu L, Du L, Wu J, Ding D, Wang J, Wang R et al.. Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasis-Associated Atherosclerosis by Inducing Mitochondrial Dysfunction in Aortic Endothelial Cells. The Journal of investigative dermatology 2026. link 14 Hazique M, Banda SV, Rizwan R, Grewal S, Thapa P, Naeem A et al.. Increased risk of stroke in patients with psoriasis: A systematic review and meta-analysis. Medicine 2026. link 15 Zheng G, Zhang Y, Su H, Yang H, Ma Z, Li L et al.. Cardiovascular-kidney-metabolic health, genetic predisposition and incident risk of psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV 2026. link 16 Torres T, Brembilla NC, Langley RG, Warren RB, Thaçi D, Kolios AGA et al.. Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensus. Journal of the European Academy of Dermatology and Venereology : JEADV 2025. link 17 Speeckaert R, Nikkels AF, Lambert J, Benhadou F, Reynaert V, Ghislain PD et al.. Belgian recommendations for managing psoriasis in a changing treatment landscape. Journal of the European Academy of Dermatology and Venereology : JEADV 2025. link 18 Vicente A, Pérez-Ferriols A, Batalla A, García-Fernandez L, Pérez B, Eiris N et al.. [Translated article] Consensus Statement From the Spanish Academy of Dermatology and Venereology (AEDV) Psoriasis Working Group (SWG) and Pediatric Working Group (PWG) on the Management of Pediatric Psoriasis. Actas dermo-sifiliograficas 2025. link 19 Fakhri Baghdad Abad A, Heidari N, Lotfi Z, Heidari A. A systematic review of novel Phosphodiesterase-4 inhibitors in the treatment of psoriasis. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2025. link 20 Sbidian E, Chaimani A, Guelimi R, Tai CC, Beytout Q, Choudhary C et al.. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. The Cochrane database of systematic reviews 2025. link 21 Dand N, Stuart PE, Bowes J, Ellinghaus D, Nititham J, Saklatvala JR et al.. GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets. Nature communications 2025. link 22 Lu L, Xu Y, Shi M, Liu A. Psychosocial interventions for psoriasis: a Bayesian network meta-analysis. The Journal of dermatological treatment 2025. link 23 Zhang L, Zhao X, Li W, Sun Y, Liu H. Switching biologic agent in patients with psoriasis: a systematic review and meta-analysis. The Journal of dermatological treatment 2025. link 24 Anheyer M, Cramer H, Ostermann T, Längler A, Anheyer D. Herbal medicine for treating psoriasis: A systematic review. Complementary therapies in medicine 2025. link 25 Kang S, Zhang D, Zhang B, Zhao C, Zhou S, Xin Y et al.. Participant Heterogeneity of Psoriasis Interventional Trials. Dermatology (Basel, Switzerland) 2025. link 26 Almutairi AG, Aloraini LI, Almutairi RR, Alfaqih AA, Alruwaili SA, Aljefri S. Ocular Manifestations of Psoriasis: A Systematic Review. Ocular immunology and inflammation 2025. link 27 Haggett MG, Lee S, Lai FYX. A systematic review of the efficacy of TYK2 inhibitors in patients with dermatological disease. The Australasian journal of dermatology 2025. link 28 Liu M, Sun Z, Tan P, Xie D, Liu Y, Feng W et al.. Associations between psoriasis and risk of 33 cancers: a Mendelian randomization study. BMC cancer 2025. link 29 . What is Psoriasis?. Pediatric dermatology 2025. link 30 Palazzo E. Exploring the Molecular Mechanisms of Psoriasis and Other Skin Disorders: Unveiling New Insights. International journal of molecular sciences 2025. link 31 Barton A. Genetics of psoriasis spectrum disease - Advances in targeted therapeutics meeting. Seminars in arthritis and rheumatism 2025. link 32 Gkini MA, Chinchay L, Lindsay CA, Franco M, Castro Ayarza JR, Duffin KC. Diagnosis and Assessment of Psoriasis for the Rheumatologist: A Workshop From the GRAPPA 2024 Annual Meeting. The Journal of rheumatology 2025. link 33 Anjaneyan G, Nayak P, Pillai JR, Cb M, Sajini L, Jagadeesan S et al.. Methotrexate dosage and laboratory monitoring in patients with psoriasis and psoriatic arthritis: A retrospective analysis of prescription patterns and financial impact in dermatology and rheumatology settings. Indian journal of dermatology, venereology and leprology 2025. link 34 Liu Z, Ma X, Chang T, Yao C, Song M, Biyue S et al.. Associations between psoriasis, psoriatic arthritis and gout or hyperuricemia: A systematic review and meta-analysis. The American journal of the medical sciences 2025. link 35 Walter S. Perception and portrayal: The depiction of psoriasis in dermatology cartoons. Clinics in dermatology 2025. link 36 Kumaran G, Carroll L, Muirhead N, Bottomley MJ. How Can Spatial Transcriptomic Profiling Advance Our Understanding of Skin Diseases?. The Journal of investigative dermatology 2025. link 37 Romiti R, de Carvalho AVE, Nakano J, Duarte GV. Highlights of the Brazilian Society of Dermatology's Brazilian Consensus on Psoriasis. Anais brasileiros de dermatologia 2025. link 38 Bowe S, Murphy M, Bourke J, Ryan C. An assessment of the prescribing preferences of Irish dermatology consultants for the treatment of severe psoriasis in the setting of a cancer diagnosis. Irish journal of medical science 2025. link 39 Wu S, Wang D, Gu X, Xiao R, Gao H, Yang B et al.. Identifying Research Hotspots and Trends in Psoriasis Literature: Autotuned Topic Modeling with Agent. The Journal of investigative dermatology 2025. link 40 Cohen JM, Bunick CG. Psoriasis: Perspectives from Irwin M. Braverman, MD. Clinics in dermatology 2025. link 41 Lau WC, Lau CB, Nambudiri V, Smith GP. Evaluating the readability of FDA-approved JAK inhibitor medication guides in dermatology. Archives of dermatological research 2025. link 42 Romanelli S, Childs B, Strand V, Armstrong AW, Perez-Chada LM, Merola JF et al.. Report of the IDEOM Meeting Adjacent to the GRAPPA 2024 Annual Meeting. The Journal of rheumatology 2025. link 43 Carvalho AVE, Galimany L, Leite L, Merino-Senekowitsch N, Armijo D, Barboza da Silva J et al.. Psoriasis treatment training in dermatology residency: a Latin American survey of faculty and residents. The Journal of dermatological treatment 2025. link 44 Reinders P, Augustin M, Stephan B, Otten M. Understanding patient priorities in teledermatology for psoriasis: A discrete choice experiment. Journal of the European Academy of Dermatology and Venereology : JEADV 2025. link 45 Zhou Y, Ma X, Guo H, Zhang S. Treatment of severe psoriasis in a hospice care patient using secukinumab, an inhibitor of interleukin-17A expression: Treatment response and changes in quality of life. International journal of clinical pharmacology and therapeutics 2025. link 46 Cheng Y, Ma J, Niu J. Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS). PloS one 2025. link 47 Inoue A, Kondo Y, Tsuruhashi S, Sakazaki Y, Irie T, Ishitsuka Y. Signal Detection of Drug-Drug Interactions Between Topical Vitamin D3 Analogs and Oral Thiazide Diuretics in Hypercalcemia: Analysis of the Japanese Drug Event Report Database. The Journal of dermatology 2025. link 48 Tang J, Liu G, Lv B. Disproportionality analysis of ixekizumab-associated adverse events in the FAERS database: A real-world pharmacovigilance study. Medicine 2025. link 49 Zhao Y, Li Z, Zhang K, Wang N. Detection of risk signals for ustekinumab in the real world using the FDA Adverse Event Reporting System (FAERS). Expert opinion on drug safety 2025. link 50 Tan H, Chen X, Ou X, Chen Y. Safety evaluation of deucravacitinib: a real-world analysis based on the FDA adverse event reporting system database. International journal of clinical pharmacy 2025. link 51 Wan Y, Zhou Y, Chen W, Li H, Huang J, Li J. Analysis and mining of brodalumab adverse events based on FAERS database. Scientific reports 2025. link 52 Fang R, Zhou Y, Han L, Chen W, Sun Y, Li J. Infection and infestation-related adverse events of biologics in psoriasis: insights from the Food and Drug Administration Adverse Event Reporting System (FAERS). Expert opinion on drug safety 2025. link 53 Huang X, Zhang C, Zhang L. Disproportionality analyses of Tapinarof-related adverse events based on the FAERS database. Archives of dermatological research 2025. link 54 He K, Zhao K, Yin T, Liu M, Liu J, Du W et al.. A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system. Scientific reports 2025. link 55 Zhao K, Xiao S, Zhao Y, Tu C. Real-world safety of deucravacitinib: insights from the Food and Drug Administration Adverse Event Reporting System. International journal of clinical pharmacy 2025. link 56 Deng K, Jiang H, Xie S, Yin M, Guo C, Huang L et al.. Comprehensive disproportionality analysis of individual case safety reports associated with Janus kinase inhibitors in psoriasis and psoriatic arthritis using the FAERS database. Frontiers in immunology 2025. link 57 Shi W, Zhao Z, Zhai Y, Ye X, Xu F. Adverse events associated with IL-23 and IL-12/23 inhibitors in the clinical management of psoriasis: a comprehensive pharmacovigilance analysis. BMC pharmacology & toxicology 2025. link 58 Zheng Y, Gao XJ, Huang JJ, Chen XM, Liao Y, Liu JM et al.. The safety assessment of ustekinumab on psoriasis and psoriatic arthritis: A real-world analysis based on the FDA adverse event reporting system database. International immunopharmacology 2025. link 59 Kridin K, Bieber K, Vorobyev A, Moderegger EL, Olbrich H, Ludwig MA et al.. Biological, as opposed to classic antipsoriatic drug or apremilast, treatment mitigates the risk of death and cardiovascular disease in psoriasis. EBioMedicine 2025. link 60 Chen TL, Huang JY, Lin HY, Chang YT, Li CY, Wei JC. Risk of major adverse cardiovascular events and venous thromboembolic events between patients with psoriasis or psoriatic arthritis on tumor necrosis factor inhibitors, interleukin 17 inhibitors, interleukin 12/23 inhibitors, and interleukin 23 inhibitors: An emulated target trial analysis. Journal of the American Academy of Dermatology 2025. link 61 Attar JA, von Martial S, Troost K, Neumeister T, Ehrchen J, Steinbrink K et al.. Impact of a dermatological rehabilitation program on cardiovascular risks of psoriasis patients. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2025. link 62 Zeng H, Shu Q, Fang J, Du H, Xue Y. Linking psoriasis to atrial fibrillation: Insights from "Association between psoriasis and atrial fibrillation: A systematic review and meta-analysis". Current problems in cardiology 2025. link 63 Amara S, Pasumarthi A, Parikh N, Kodali N, Lebwohl M, Monks G. Psoriasis management tree based on comorbidity. International journal of dermatology 2025. link 64 Huynh TN, Yamazaki F, Konrad RJ, Nishikawa Y, Tanaka A, Son Y et al.. Circulating CD31 and resistin levels reflect different stages of coronary atherosclerosis in patients with psoriasis. The Journal of dermatology 2025. link 65 Oon HH, Tan C, Aw DCW, Chong WS, Koh HY, Leung YY et al.. 2023 guidelines on the management of psoriasis by the Dermatological Society of Singapore. Annals of the Academy of Medicine, Singapore 2024. link 66 Choon SE, Foley PA, Asawanonda P, Fujita H, Jo SJ, Shi YL et al.. Asia-Pacific consensus recommendations on the management of generalized pustular psoriasis. The Journal of dermatology 2024. link 67 Jain H, Odat RM, Goyal A, Jain J, Dey D, Ahmed M et al.. Association between psoriasis and atrial fibrillation: A Systematic review and meta-analysis. Current problems in cardiology 2024. link 68 Wu D, Zhou X, Wu F, Cai R, Liu J, Bai Y. Association between psoriasis and asthma: a systematic review and bidirectional meta-analysis. BMC pulmonary medicine 2024. link 69 Guo M, Su J, Zheng S, Chen B. Sleep in psoriasis: A meta-analysis. Journal of psychosomatic research 2024. link 70 James WA, Rosenberg AL, Wu JJ, Hsu S, Armstrong A, Wallace EB et al.. Full Guidelines-From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology 2024. link 71 Puig L, Notario J, López-Ferrer A, Scheneller-Pavelescu L, Pérez B, Galache C et al.. [Translated article] Recommendations from the Spanish Academy of Dermatology and Venereology Psoriasis Working Group on the Management of Patients with Cancer and Psoriasis. Actas dermo-sifiliograficas 2024. link 72 Chalupczak NV, Lio PA. Complementary and Alternative Therapies for Psoriasis. Archives of dermatological research 2024. link 73 Thomas SE, Barenbrug L, Hannink G, Seyger MMB, de Jong EMGJ, van den Reek JMPA. Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis. Drugs 2024. link 74 Hjort G, Schwarz CW, Skov L, Loft N. Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis: A Meta-analysis. JAMA dermatology 2024. link 75 Blauvelt A, Noe MH. The Best Psoriasis Medications Emerge. JAMA dermatology 2024. link 76 Huang IH, Wu PC, Chiu HY, Huang YH. Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis. American journal of clinical dermatology 2024. link 77 Sitton B, Walker T, Mital R, Varra V, Kaffenberger J. Antistreptococcal treatment of psoriasis: a systematic review. Archives of dermatological research 2024. link 78 Sun X, Cui Z, Wang Q, Liu L, Ding X, Wang J et al.. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence. Autoimmunity reviews 2024. link 79 Tsai TF, Tada Y, Kung C, Zhong Y, Cichewicz A, Borkowska K et al.. Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis. The Journal of dermatology 2024. link 80 Rachadi H, Chiheb S. Dermoscopic features of nail psoriasis: a systematic review. International journal of dermatology 2024. link 81 Husein-ElAhmed H, Husein-ElAhmed S. Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of Psoriasis Area and Severity Index score. Clinical and experimental dermatology 2024. link 82 Ubago-Rodríguez A, Quiñones-Vico MI, Sánchez-Díaz M, Sanabria-de la Torre R, Sierra-Sánchez Á, Montero-Vílchez T et al.. Challenges in Psoriasis Research: A Systematic Review of Preclinical Models. Dermatology (Basel, Switzerland) 2024. link 83 Wang J, Yu Y, Liu L, Wang C, Sun X, Zhou Y et al.. Global prevalence of obesity in patients with psoriasis: An analysis in the past two decades. Autoimmunity reviews 2024. link 84 Patra P, Harrison T. Trace elements in psoriasis presentation and treatment. Archives of dermatological research 2024. link 85 Shah V, Larson A, Jafferany M. Exploring the psychological impact of childhood-onset psoriasis: a systematic review. Clinical and experimental dermatology 2024. link 86 Perry M. Psoriasis: an overview. British journal of nursing (Mark Allen Publishing) 2024. link 87 Drozdowski R, Jain N, Gronbeck C, Feng H. Disparities in Care for Psoriasis. Dermatologic clinics 2024. link 88 Ball GD, Yee D, Zhang AJ, Perez-Chada LM, Strand V, Merola JF et al.. Report of the IDEOM Meeting Adjacent to the GRAPPA 2023 Annual Meeting. The Journal of rheumatology 2024. link 89 Johnsson HJ, Ayan G, Coras R, Grynszpan R, Herrera S, Jethwa H et al.. Young-GRAPPA 2023: The Future Is Bright. The Journal of rheumatology 2024. link 90 Kemény L. Editor's highlights - October, 2024. International journal of dermatology 2024. link 91 Hartmann Schatloff D, Retamal Altbir C, Valenzuela F. The role of excimer light in dermatology: a review. Anais brasileiros de dermatologia 2024. link 92 Tibi A, Khamaysi Z, Avitan-Hersh E. To ASLO or Not to ASLO: Utility of the ASLO Test in Dermatology. The Israel Medical Association journal : IMAJ 2024. link 93 Shajirat Z, Parandeh R, Pazyar N, Azizi A. Developing and evaluating a mobile-based teledermatology system for skin lesion diagnosis in Iran. Scientific reports 2024. link 94 George A, Lansang RP, Lansang P, Gooderham M. A Practical Guide to Using Biologics in Pediatric Dermatology. Journal of cutaneous medicine and surgery 2024. link 95 Vilarrasa E, Rivera R, Eiris N, Carretero G, de la Cueva P, Carrascosa JM. [Translated article] Approach to the Epidemiology, Disease Management, and Current Challenges in the Management of Generalized Pustular Psoriasis Through a Survey Conducted Among Spanish Dermatologists. Actas dermo-sifiliograficas 2024. link 96 Zhang AJ, Perez-Chada LM, Strand V, Armstrong AW, Gottlieb AB, Merola JF. GRAPPA 2023 Annual Meeting Report: Hot Topic Session on Measurement of Musculoskeletal Symptoms in Psoriatic Disease. The Journal of rheumatology 2024. link 97 Sánchez-Díaz M, Flórez Á, Ara-Martín M, Arias-Santiago S, Botella-Estrada R, Cañueto J et al.. [Translated article] Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study. Actas dermo-sifiliograficas 2024. link 98 Maul JT, Maul LV, Didaskalu JA, Valenzuela F, Romiti R, Peterson H et al.. Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis. Acta dermato-venereologica 2024. link 99 Feng F, Li R, Tian R, Wu X, Zhang N, Nie Z. The causal relationship between gut microbiota and immune skin diseases: A bidirectional Mendelian randomization. PloS one 2024. link 100 Eshwar V, Kamath A. Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database. Scientific reports 2024. link

Original source

[1]
Generalized Pustular Psoriasis: Review and Consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. — Puig L, Carrascosa JM, Rivera R, Vilarrasa E, de la Cueva P, López-Ferrer A Actas dermo-sifiliograficas (2026)
[2]
Relative Efficacy of Immunomodulatory Monotherapies for Psoriasis of the Scalp: A Network Meta-Analysis Study. — Gupta AK, Bamimore MA, Wang T, Piguet V, Talukder M Journal of cosmetic dermatology (2026)
[3]
Joint Assessment Matters: Diagnostic and Therapeutic Benefits of Interdisciplinary Psoriasis Care. — Dege T, Steffens O, Kiesel Ö, Bychkova I, Leichtfuss L, Schulze-Hagen T et al. Advances in therapy (2026)
[4]
ChatGPT and DeepSeek in Dermatologic Practice: Do Artificial Intelligence Models Adhere to Psoriasis Treatment Guidelines? — Demet AN, Kaynak E, Ahmet M Journal of drugs in dermatology : JDD (2026)
[5]
Toward the definition of moderate psoriasis: an expert opinion. — Costanzo A, Bardazzi F, Burlando M, Campanati A, Carrera C, Dapavo P et al. The Journal of dermatological treatment (2026)
[6]
Childhood infections as predisposing factors to developing psoriasis vulgaris into early adulthood. — Thimjo J, Das D, Enerbäck C, Ludvigsson J The British journal of dermatology (2026)
[7]
Disproportionality analysis of adverse events associated with bimekizumab: a real-world study based on FDA Adverse Event Reporting System (FAERS) Database. — Lin X, Guo L, Lin T, Yan C, Huang X, Cheng Y et al. Naunyn-Schmiedeberg's archives of pharmacology (2026)
[8]
Atherogenic Lipoprotein Burden, Metabolic Stress and Immune Activation Associated with Coronary Atherosclerosis in Patients with Psoriasis. — Djukanovic L, Skiljevic D, Nikolic M, Malinic M, Popadic S, Radmili O et al. International journal of molecular sciences (2026)
[9]
Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis and Its Association With Risk of Major Adverse Cardiac Events. — Geiger J, Gill B, Liew J, Putman M, Singla S The Journal of rheumatology (2026)
[10]
Cardiovascular Imaging in Psoriasis: A Critical Review of Current Evidence, Techniques, and Therapeutic Implications. — Tartaglia J, Ponzano M, Mazzetto R, Sernicola A, Ciolfi C, Tona F et al. American journal of clinical dermatology (2026)
[11]
Mortality Outcomes in Patients With Plaque Psoriasis and Hidradenitis Suppurativa: The Role of Biologic Therapy. — Rivera-Díaz R, Joven B, Gotor-Rivera A, Hernández J Actas dermo-sifiliograficas (2026)
[12]
Clinical Profiles of Psoriasis Patients With Coronary Artery Calcification and Assessment of Acute Coronary Syndrome Risk Factors Using Coronary Computed Tomography Angiography-Estimated Fractional Flow Reserve. — Watabe H, Ishibashi Y, Go K, Nakajima K, Tanabe Y, Akashi YJ et al. The Journal of dermatology (2026)
[13]
Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasis-Associated Atherosclerosis by Inducing Mitochondrial Dysfunction in Aortic Endothelial Cells. — Zhu L, Du L, Wu J, Ding D, Wang J, Wang R et al. The Journal of investigative dermatology (2026)
[14]
Increased risk of stroke in patients with psoriasis: A systematic review and meta-analysis. — Hazique M, Banda SV, Rizwan R, Grewal S, Thapa P, Naeem A et al. Medicine (2026)
[15]
Cardiovascular-kidney-metabolic health, genetic predisposition and incident risk of psoriasis. — Zheng G, Zhang Y, Su H, Yang H, Ma Z, Li L et al. Journal of the European Academy of Dermatology and Venereology : JEADV (2026)
[16]
Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensus. — Torres T, Brembilla NC, Langley RG, Warren RB, Thaçi D, Kolios AGA et al. Journal of the European Academy of Dermatology and Venereology : JEADV (2025)
[17]
Belgian recommendations for managing psoriasis in a changing treatment landscape. — Speeckaert R, Nikkels AF, Lambert J, Benhadou F, Reynaert V, Ghislain PD et al. Journal of the European Academy of Dermatology and Venereology : JEADV (2025)
[18]
[Translated article] Consensus Statement From the Spanish Academy of Dermatology and Venereology (AEDV) Psoriasis Working Group (SWG) and Pediatric Working Group (PWG) on the Management of Pediatric Psoriasis. — Vicente A, Pérez-Ferriols A, Batalla A, García-Fernandez L, Pérez B, Eiris N et al. Actas dermo-sifiliograficas (2025)
[19]
A systematic review of novel Phosphodiesterase-4 inhibitors in the treatment of psoriasis. — Fakhri Baghdad Abad A, Heidari N, Lotfi Z, Heidari A Inflammation research : official journal of the European Histamine Research Society ... [et al.] (2025)
[20]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. — Sbidian E, Chaimani A, Guelimi R, Tai CC, Beytout Q, Choudhary C et al. The Cochrane database of systematic reviews (2025)
[21]
GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets. — Dand N, Stuart PE, Bowes J, Ellinghaus D, Nititham J, Saklatvala JR et al. Nature communications (2025)
[22]
Psychosocial interventions for psoriasis: a Bayesian network meta-analysis. — Lu L, Xu Y, Shi M, Liu A The Journal of dermatological treatment (2025)
[23]
Switching biologic agent in patients with psoriasis: a systematic review and meta-analysis. — Zhang L, Zhao X, Li W, Sun Y, Liu H The Journal of dermatological treatment (2025)
[24]
Herbal medicine for treating psoriasis: A systematic review. — Anheyer M, Cramer H, Ostermann T, Längler A, Anheyer D Complementary therapies in medicine (2025)
[25]
Participant Heterogeneity of Psoriasis Interventional Trials. — Kang S, Zhang D, Zhang B, Zhao C, Zhou S, Xin Y et al. Dermatology (Basel, Switzerland) (2025)
[26]
Ocular Manifestations of Psoriasis: A Systematic Review. — Almutairi AG, Aloraini LI, Almutairi RR, Alfaqih AA, Alruwaili SA, Aljefri S Ocular immunology and inflammation (2025)
[27]
A systematic review of the efficacy of TYK2 inhibitors in patients with dermatological disease. — Haggett MG, Lee S, Lai FYX The Australasian journal of dermatology (2025)
[28]
Associations between psoriasis and risk of 33 cancers: a Mendelian randomization study. — Liu M, Sun Z, Tan P, Xie D, Liu Y, Feng W et al. BMC cancer (2025)
[29]
What is Psoriasis? Pediatric dermatology (2025)
[30]
Exploring the Molecular Mechanisms of Psoriasis and Other Skin Disorders: Unveiling New Insights. — Palazzo E International journal of molecular sciences (2025)
[31]
Genetics of psoriasis spectrum disease - Advances in targeted therapeutics meeting. — Barton A Seminars in arthritis and rheumatism (2025)
[32]
Diagnosis and Assessment of Psoriasis for the Rheumatologist: A Workshop From the GRAPPA 2024 Annual Meeting. — Gkini MA, Chinchay L, Lindsay CA, Franco M, Castro Ayarza JR, Duffin KC The Journal of rheumatology (2025)
[33]
Methotrexate dosage and laboratory monitoring in patients with psoriasis and psoriatic arthritis: A retrospective analysis of prescription patterns and financial impact in dermatology and rheumatology settings. — Anjaneyan G, Nayak P, Pillai JR, Cb M, Sajini L, Jagadeesan S et al. Indian journal of dermatology, venereology and leprology (2025)
[34]
Associations between psoriasis, psoriatic arthritis and gout or hyperuricemia: A systematic review and meta-analysis. — Liu Z, Ma X, Chang T, Yao C, Song M, Biyue S et al. The American journal of the medical sciences (2025)
[35]
Perception and portrayal: The depiction of psoriasis in dermatology cartoons. — Walter S Clinics in dermatology (2025)
[36]
How Can Spatial Transcriptomic Profiling Advance Our Understanding of Skin Diseases? — Kumaran G, Carroll L, Muirhead N, Bottomley MJ The Journal of investigative dermatology (2025)
[37]
Highlights of the Brazilian Society of Dermatology's Brazilian Consensus on Psoriasis. — Romiti R, de Carvalho AVE, Nakano J, Duarte GV Anais brasileiros de dermatologia (2025)
[38]
An assessment of the prescribing preferences of Irish dermatology consultants for the treatment of severe psoriasis in the setting of a cancer diagnosis. — Bowe S, Murphy M, Bourke J, Ryan C Irish journal of medical science (2025)
[39]
Identifying Research Hotspots and Trends in Psoriasis Literature: Autotuned Topic Modeling with Agent. — Wu S, Wang D, Gu X, Xiao R, Gao H, Yang B et al. The Journal of investigative dermatology (2025)
[40]
Psoriasis: Perspectives from Irwin M. Braverman, MD. — Cohen JM, Bunick CG Clinics in dermatology (2025)
[41]
Evaluating the readability of FDA-approved JAK inhibitor medication guides in dermatology. — Lau WC, Lau CB, Nambudiri V, Smith GP Archives of dermatological research (2025)
[42]
Report of the IDEOM Meeting Adjacent to the GRAPPA 2024 Annual Meeting. — Romanelli S, Childs B, Strand V, Armstrong AW, Perez-Chada LM, Merola JF et al. The Journal of rheumatology (2025)
[43]
Psoriasis treatment training in dermatology residency: a Latin American survey of faculty and residents. — Carvalho AVE, Galimany L, Leite L, Merino-Senekowitsch N, Armijo D, Barboza da Silva J et al. The Journal of dermatological treatment (2025)
[44]
Understanding patient priorities in teledermatology for psoriasis: A discrete choice experiment. — Reinders P, Augustin M, Stephan B, Otten M Journal of the European Academy of Dermatology and Venereology : JEADV (2025)
[45]
Treatment of severe psoriasis in a hospice care patient using secukinumab, an inhibitor of interleukin-17A expression: Treatment response and changes in quality of life. — Zhou Y, Ma X, Guo H, Zhang S International journal of clinical pharmacology and therapeutics (2025)
[46]
Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS). — Cheng Y, Ma J, Niu J PloS one (2025)
[47]
Signal Detection of Drug-Drug Interactions Between Topical Vitamin D3 Analogs and Oral Thiazide Diuretics in Hypercalcemia: Analysis of the Japanese Drug Event Report Database. — Inoue A, Kondo Y, Tsuruhashi S, Sakazaki Y, Irie T, Ishitsuka Y The Journal of dermatology (2025)
[48]
Disproportionality analysis of ixekizumab-associated adverse events in the FAERS database: A real-world pharmacovigilance study. — Tang J, Liu G, Lv B Medicine (2025)
[49]
Detection of risk signals for ustekinumab in the real world using the FDA Adverse Event Reporting System (FAERS). — Zhao Y, Li Z, Zhang K, Wang N Expert opinion on drug safety (2025)
[50]
Safety evaluation of deucravacitinib: a real-world analysis based on the FDA adverse event reporting system database. — Tan H, Chen X, Ou X, Chen Y International journal of clinical pharmacy (2025)
[51]
Analysis and mining of brodalumab adverse events based on FAERS database. — Wan Y, Zhou Y, Chen W, Li H, Huang J, Li J Scientific reports (2025)
[52]
Infection and infestation-related adverse events of biologics in psoriasis: insights from the Food and Drug Administration Adverse Event Reporting System (FAERS). — Fang R, Zhou Y, Han L, Chen W, Sun Y, Li J Expert opinion on drug safety (2025)
[53]
Disproportionality analyses of Tapinarof-related adverse events based on the FAERS database. — Huang X, Zhang C, Zhang L Archives of dermatological research (2025)
[54]
A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system. — He K, Zhao K, Yin T, Liu M, Liu J, Du W et al. Scientific reports (2025)
[55]
Real-world safety of deucravacitinib: insights from the Food and Drug Administration Adverse Event Reporting System. — Zhao K, Xiao S, Zhao Y, Tu C International journal of clinical pharmacy (2025)
[56]
Comprehensive disproportionality analysis of individual case safety reports associated with Janus kinase inhibitors in psoriasis and psoriatic arthritis using the FAERS database. — Deng K, Jiang H, Xie S, Yin M, Guo C, Huang L et al. Frontiers in immunology (2025)
[57]
Adverse events associated with IL-23 and IL-12/23 inhibitors in the clinical management of psoriasis: a comprehensive pharmacovigilance analysis. — Shi W, Zhao Z, Zhai Y, Ye X, Xu F BMC pharmacology & toxicology (2025)
[58]
The safety assessment of ustekinumab on psoriasis and psoriatic arthritis: A real-world analysis based on the FDA adverse event reporting system database. — Zheng Y, Gao XJ, Huang JJ, Chen XM, Liao Y, Liu JM et al. International immunopharmacology (2025)
[59]
Biological, as opposed to classic antipsoriatic drug or apremilast, treatment mitigates the risk of death and cardiovascular disease in psoriasis. — Kridin K, Bieber K, Vorobyev A, Moderegger EL, Olbrich H, Ludwig MA et al. EBioMedicine (2025)
[60]
Risk of major adverse cardiovascular events and venous thromboembolic events between patients with psoriasis or psoriatic arthritis on tumor necrosis factor inhibitors, interleukin 17 inhibitors, interleukin 12/23 inhibitors, and interleukin 23 inhibitors: An emulated target trial analysis. — Chen TL, Huang JY, Lin HY, Chang YT, Li CY, Wei JC Journal of the American Academy of Dermatology (2025)
[61]
Impact of a dermatological rehabilitation program on cardiovascular risks of psoriasis patients. — Attar JA, von Martial S, Troost K, Neumeister T, Ehrchen J, Steinbrink K et al. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG (2025)
[62]
Linking psoriasis to atrial fibrillation: Insights from "Association between psoriasis and atrial fibrillation: A systematic review and meta-analysis". — Zeng H, Shu Q, Fang J, Du H, Xue Y Current problems in cardiology (2025)
[63]
Psoriasis management tree based on comorbidity. — Amara S, Pasumarthi A, Parikh N, Kodali N, Lebwohl M, Monks G International journal of dermatology (2025)
[64]
Circulating CD31 and resistin levels reflect different stages of coronary atherosclerosis in patients with psoriasis. — Huynh TN, Yamazaki F, Konrad RJ, Nishikawa Y, Tanaka A, Son Y et al. The Journal of dermatology (2025)
[65]
2023 guidelines on the management of psoriasis by the Dermatological Society of Singapore. — Oon HH, Tan C, Aw DCW, Chong WS, Koh HY, Leung YY et al. Annals of the Academy of Medicine, Singapore (2024)
[66]
Asia-Pacific consensus recommendations on the management of generalized pustular psoriasis. — Choon SE, Foley PA, Asawanonda P, Fujita H, Jo SJ, Shi YL et al. The Journal of dermatology (2024)
[67]
Association between psoriasis and atrial fibrillation: A Systematic review and meta-analysis. — Jain H, Odat RM, Goyal A, Jain J, Dey D, Ahmed M et al. Current problems in cardiology (2024)
[68]
Association between psoriasis and asthma: a systematic review and bidirectional meta-analysis. — Wu D, Zhou X, Wu F, Cai R, Liu J, Bai Y BMC pulmonary medicine (2024)
[69]
Sleep in psoriasis: A meta-analysis. — Guo M, Su J, Zheng S, Chen B Journal of psychosomatic research (2024)
[70]
Full Guidelines-From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. — James WA, Rosenberg AL, Wu JJ, Hsu S, Armstrong A, Wallace EB et al. Journal of the American Academy of Dermatology (2024)
[71]
[Translated article] Recommendations from the Spanish Academy of Dermatology and Venereology Psoriasis Working Group on the Management of Patients with Cancer and Psoriasis. — Puig L, Notario J, López-Ferrer A, Scheneller-Pavelescu L, Pérez B, Galache C et al. Actas dermo-sifiliograficas (2024)
[72]
Complementary and Alternative Therapies for Psoriasis. — Chalupczak NV, Lio PA Archives of dermatological research (2024)
[73]
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis. — Thomas SE, Barenbrug L, Hannink G, Seyger MMB, de Jong EMGJ, van den Reek JMPA Drugs (2024)
[74]
Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis: A Meta-analysis. — Hjort G, Schwarz CW, Skov L, Loft N JAMA dermatology (2024)
[75]
The Best Psoriasis Medications Emerge. — Blauvelt A, Noe MH JAMA dermatology (2024)
[76]
Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis. — Huang IH, Wu PC, Chiu HY, Huang YH American journal of clinical dermatology (2024)
[77]
Antistreptococcal treatment of psoriasis: a systematic review. — Sitton B, Walker T, Mital R, Varra V, Kaffenberger J Archives of dermatological research (2024)
[78]
Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence. — Sun X, Cui Z, Wang Q, Liu L, Ding X, Wang J et al. Autoimmunity reviews (2024)
[79]
Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis. — Tsai TF, Tada Y, Kung C, Zhong Y, Cichewicz A, Borkowska K et al. The Journal of dermatology (2024)
[80]
Dermoscopic features of nail psoriasis: a systematic review. — Rachadi H, Chiheb S International journal of dermatology (2024)
[81]
Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of Psoriasis Area and Severity Index score. — Husein-ElAhmed H, Husein-ElAhmed S Clinical and experimental dermatology (2024)
[82]
Challenges in Psoriasis Research: A Systematic Review of Preclinical Models. — Ubago-Rodríguez A, Quiñones-Vico MI, Sánchez-Díaz M, Sanabria-de la Torre R, Sierra-Sánchez Á, Montero-Vílchez T et al. Dermatology (Basel, Switzerland) (2024)
[83]
Global prevalence of obesity in patients with psoriasis: An analysis in the past two decades. — Wang J, Yu Y, Liu L, Wang C, Sun X, Zhou Y et al. Autoimmunity reviews (2024)
[84]
Trace elements in psoriasis presentation and treatment. — Patra P, Harrison T Archives of dermatological research (2024)
[85]
Exploring the psychological impact of childhood-onset psoriasis: a systematic review. — Shah V, Larson A, Jafferany M Clinical and experimental dermatology (2024)
[86]
Psoriasis: an overview. — Perry M British journal of nursing (Mark Allen Publishing) (2024)
[87]
Disparities in Care for Psoriasis. — Drozdowski R, Jain N, Gronbeck C, Feng H Dermatologic clinics (2024)
[88]
Report of the IDEOM Meeting Adjacent to the GRAPPA 2023 Annual Meeting. — Ball GD, Yee D, Zhang AJ, Perez-Chada LM, Strand V, Merola JF et al. The Journal of rheumatology (2024)
[89]
Young-GRAPPA 2023: The Future Is Bright. — Johnsson HJ, Ayan G, Coras R, Grynszpan R, Herrera S, Jethwa H et al. The Journal of rheumatology (2024)
[90]
Editor's highlights - October, 2024. — Kemény L International journal of dermatology (2024)
[91]
The role of excimer light in dermatology: a review. — Hartmann Schatloff D, Retamal Altbir C, Valenzuela F Anais brasileiros de dermatologia (2024)
[92]
To ASLO or Not to ASLO: Utility of the ASLO Test in Dermatology. — Tibi A, Khamaysi Z, Avitan-Hersh E The Israel Medical Association journal : IMAJ (2024)
[93]
Developing and evaluating a mobile-based teledermatology system for skin lesion diagnosis in Iran. — Shajirat Z, Parandeh R, Pazyar N, Azizi A Scientific reports (2024)
[94]
A Practical Guide to Using Biologics in Pediatric Dermatology. — George A, Lansang RP, Lansang P, Gooderham M Journal of cutaneous medicine and surgery (2024)
[95]
[Translated article] Approach to the Epidemiology, Disease Management, and Current Challenges in the Management of Generalized Pustular Psoriasis Through a Survey Conducted Among Spanish Dermatologists. — Vilarrasa E, Rivera R, Eiris N, Carretero G, de la Cueva P, Carrascosa JM Actas dermo-sifiliograficas (2024)
[96]
GRAPPA 2023 Annual Meeting Report: Hot Topic Session on Measurement of Musculoskeletal Symptoms in Psoriatic Disease. — Zhang AJ, Perez-Chada LM, Strand V, Armstrong AW, Gottlieb AB, Merola JF The Journal of rheumatology (2024)
[97]
[Translated article] Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study. — Sánchez-Díaz M, Flórez Á, Ara-Martín M, Arias-Santiago S, Botella-Estrada R, Cañueto J et al. Actas dermo-sifiliograficas (2024)
[98]
Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis. — Maul JT, Maul LV, Didaskalu JA, Valenzuela F, Romiti R, Peterson H et al. Acta dermato-venereologica (2024)
[99]
The causal relationship between gut microbiota and immune skin diseases: A bidirectional Mendelian randomization. — Feng F, Li R, Tian R, Wu X, Zhang N, Nie Z PloS one (2024)
[100]
Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database. — Eshwar V, Kamath A Scientific reports (2024)

Share:Twitter Reddit LinkedIn